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2’,3’-Dideoxynucleosides and 2’,3’-didehydro-2’,3’-
dideoxynucleosides are nucleoside reverse transcriptase 
inhibitors (NRTIs). Some of them have been found effective for 
the treatment of HIV infections.  These NRTIs1 inhibit the viral 
replication by terminating DNA polymerization. One of the 
efforts to improve the therapeutic potential of nucleoside 
analogues for treating viral infections is directed towards prodrug 
development. 
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Figure 1. Structure of anti-HIV nucleosides 
Prodrug approaches have been developed for increasing oral 
absorption and cellular penetration of modified nucleos(t)ides. In 
addition, prodrugs are also used for tissue specific delivery of 
nucleotides, and for kinase bypass strategies. These prodrug 
strategies have the aim to mask the anionic phosphate moiety of 
nucleotides, and to deliver the modified nucleos(t)ides (in blood 
or in cells) involving enzymatic degradation reactions. One of the 
approaches that was followed in the past is synthesis of 
phospholipid prodrugs of modified nucleosides. Hostetler et al 
has demonstrated that the acyclovir diphosphate 
dimeristoylglycerol prodrug delivers acyclovir monophosphate 
inside cells.2 Acyl nucleotide3 derivatives of d4T and AZT, as 
well as O-alkyl-5’,5’-dinucleoside phosphates of 
AZT/cordycepin4 have been synthesized. Generally, the anti-HIV 
efficacy of the prodrug was lower3,4 or similar3 than that of the 
parent nucleotide. Many more phosphodiester prodrugs of 
modified nucleosides have been studied5 but generally it is 
believed that mono alkyl/aryl phosphodiesters are unsuitable for 
the intracellular delivery of nucleotides.6 In the case of d4A and 
d4C, 5’-methyl and 5’’-phenyl phosphate diesters shows in vitro 
anti-HIV activity comparable to those of the parent nucleoside.7 
In the present work we report the synthesis and antiviral activity 
of phospholipid conjugates of d4A, d4T, ddC. Two types of 
lipids have been considered i.e. (±)-α-hydroxy stearic acid and 
(±)-β-hydroxy stearic acid. It is hypothesized that the lipid 
moiety may help cell penetration while the -carboxylic acid 
function may assist in phosphodiester bond cleavage.8 Dependent 
on which ester bond is cleaved (C5’-O-P or CH-O-P), either the 
nucleoside or the nucleotide can be delivered in the cell. 
Additional factors which may complicate the predictability of the 
results are that the stability of 5’-phosphodiester conjugates of 
nucleoside with an α-carboxylate group could be base dependent 
and that the role of phosphodiesterase enzymes in the cleavage of 
the lipid conjugates is unknown. Intramolecular catalysis of P-O 
or P-N bond cleavage (to liberate the nucleoside or nucleotide by 
chemical degradation of the prodrug) occurs via a 5-membered 
(α-COOH) or a 6-membered (β-COOH) intermediate, and both 
possibilities have been investigated. A prodrug of AZT was not 
included in this study. To evaluate the potential of a new prodrug 
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concept, results are more pronounced when using a lower active 
or almost inactive nucleoside as model compound, rather than a 
very potent congener. 
Stavudine (d4T) 1 is prepared by a two-step method starting 
from thymidine as previously reported.9 The synthesis of 2’, 3’-
didehydro-2’, 3’-dideoxyadenosine 2 has been accomplished as 
previously described,10,11 by converting the vicinal diol of 
adenosine to olefin using Corey-Winter reaction conditions. The 
nucleoside ddC 3 is commercially available. The methyl (±)-α-
hydroxy stearate 5 is prepared in three steps from stearic acid 4 
by bromination12 using Hell-Volhard-Zelinsky conditions 
followed by hydrolysis13 and esterification14 in 88 % overall yield 
(Scheme 1). 
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Scheme 1. a) PBr3, Br2, 95°C, 6h; b) aq.NaOH, 85°C, 3h; c) 
TMSCl, DMP, MeOH, r.t. overnight; d)  2-cyanoethyl N,N-
diisopropylchlorophosphoramidite, dry DCM,  1H-tetrazole, 
0°C-r.t. 15min. 
The methyl (±)-β-hydroxy stearate 8 was synthesized by the 
procedure described by Masamune15 which involves 
homologation of palmitic acid 7 using in situ generated 
magnesium monomethylmalonate16 to a preformed acyl 
imidazole to produce the β-keto stearic acid methyl ester, which 
is reduced17 with sodium borohydride in ethanol providing 818 in 
77 % overall yield (Scheme 2). 
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Scheme 2. a) CDI, MgCl2, K+ -O2CCH2CO2CH3, THF, r.t. 
overnight; b) NaBH4, EtOH, 0°C-r.t. 15 min. 
The phosphoramidite approach was used for the synthesis of 
the lipid-nucleotide conjugates. In the case of thymine 
nucleoside, the 5’-O-phosphoramidite of d4T (9)19 was coupled 
with the hydroxylated fatty acid esters 5 and 8 yielding the 
phosphite intermediates 10 and 11 which were subsequently 
oxidized using aqueous iodine in Pyridine/THF resulting in the 
formation of 12 and 13. (Scheme 3). 
a
10: R1 = CH3 (CH2)15-, R2= -COOCH3
b
12:R1 = CH3 (CH2)15-, R2= -COOCH3
11: R1= CH3 (CH2)14-, R2= -(CH2)- COOCH3
13:R1= CH3 (CH2)14-, R2= -(CH2)-COOCH3
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Scheme 3. a) 5 for 10 and 8 for 11, 1H-tetrazole, dry DCM, 
r.t. 4h;  b) aq. iodine in pyridine/THF, r.t. 30 min 
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14:R1 = CH3 (CH2)15-, R2= -COOCH3, B=adenine-9-yl
16: R1 = CH3 (CH2)15-, R2= -COOCH3, B=cytosin-1-yl
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Scheme 4. a) 2,1H-tetrazole, dry DCM, r.t. 4h; b) aq. iodine in pyridine/THF, r.t. 30 min; c) 3, 1H-tetrazole, dry DCM, r.t. 4h. 
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12: R1 = CH3 (CH2)15-, R2 = -COOCH3, X-Y = CH=CH, B=thymin-1-yl
13: R1 = CH3 (CH2)14-, R2 = -(CH2)-COOCH3, X-Y = CH=CH, B=thymin-1-yl
15: R1 = CH3 (CH2)15-, R2 = -COOCH3, X-Y = CH=CH, B=adenin-9-yl
17: R1 = CH3 (CH2)15-, R2 = -COOCH3, X-Y = CH2-CH2, B=cytocin-1-yl
18: R1 = CH3 (CH2)15-, R2 = -COONa+, X-Y = CH=CH, B=thymin-1-yl
19: R1 = CH3 (CH2)14-, R2 = -(CH2)-COONa+, X-Y = CH=CH, B=thym-1-yl
20: R1 = CH3 (CH2)15-, R2 = -COONa+, X-Y = CH=CH, B=adenine-9-yl
21: R1 = CH3 (CH2)15-, R2 = -COONa+, X-Y = CH2-CH2; B=cytosin-1-yl  
Scheme 5. a) aq. Ammonia:MeOH (1:0.5) , r.t. 36h b) Ion exchange, Na+ form. 
In the case of cytosine and adenine nucleotides, the 
phosphoramidite derivative of the (±)-α-hydroxy stearic methyl 
ester 6 was first synthesized and coupled with the nucleoside 
analogue. The phosphoramidite 6 was obtained as a 
diastereomeric mixture in 56% yield. The reverse approach (as 
used for the synthesis of the thymine analogues) is lower 
yielding. 
The d4A and ddC conjugates were obtained by the reaction of 
6 with d4A and ddC, followed by oxidation of the intermediates 
14 and 16 to produce 15 and 17 respectively (Scheme 4). 
Deprotection of the phosphotriesters 12, 13, 15 and 17 was first 
carried out by removal of the cyanoethyl protecting group with 
DBU in THF, followed by hydrolysis of the methyl ester with 1N 
sodium hydroxide in MeOH. However, the yields were moderate 
and several side products were formed. Therefore we turned to a 
one-step deprotection procedure using an aqueous 
ammonia/MeOH mixture. (Scheme 5). 
The lipid-nucleotide conjugates 18-21 were purified on a 
Dowex-50 Na+ column followed by lyophilization. Biological 
activity was determined on the diastereomeric mixtures. 
The activity of the phosphodiester analogues of d4A-20, ddC-
21, d4T-18, 19 against HIV-1 and HIV-2 was determined 
including the dideoxy nucleosides d4A, ddC, d4T as reference 
compounds. The anti-HIV activity and cytotoxicity of the 
compounds were evaluated against wild-type HIV-1 and HIV-2 
in MT-4 cell cultures. Anti-HIV-2 activity was also determined 
in CEM cells as well as in thymidine kinase-deficient CEM 
(CEM/TK-) cell cultures. The α-hydroxy D4T derivative 18 has 
an IC50 of  0.4 µM against HIV-1 and HIV-2 in MT-4 cells, but 
was not active in CEM cells. Compound 19 (the β–hydroxy d4T 
conjugate) is about 30 times less active than the α–hydroxy d4T 
analogue. However both compound 18 and 19 are less active than 
the parent nucleoside (d4T). Similar results are obtained for the 
ddC lipid conjugate 21 i.e. the parent nucleoside (ddC) is more 
active than the potential prodrug 21, as well in MT-4 cells as in 
CEM/0 cells.  
Between the three α-hydroxy nucleoside conjugates tested, 
d4A takes a particular place. The parent d4A itself is an anti-HIV 
nucleoside with very low activity as well in MT-4 cells as in 
CEM/0 cells. Conjugation of d4A-MP with α-hydroxy stearic 
acid leads to an increase in activity of at least a factor 500 in MT-
4 cells. The activity is similar against HIV-1 and against HIV-2. 
Previously, a methyl phosphate diester was reported as a 
potential prodrug of d4A,7 however, with no increase in antiviral 
potency. The observation that the activity of 20 in CEM/K- cells 
is lower than in CEM/0 cells suggests that the prodrug of d4A 
does not deliver d4A-MP in the cells.  
In conclusion, hydroxy fatty acid conjugates of d4T-MP, d4A-
MP and ddC-MP have been prepared as prodrugs for their 
potential ability to deliver the antiviral nucleosides and/or 
nucleotides into the cell. Only in the case of d4A, increased 
antiviral activity against HIV-1 and HIV-2 has been observed. It 
therefore seems that this prodrug approach is base specific. The 
inactivity of the d4A conjugate in CEM/TK- cells suggests that 
the modified nucleosides rather than the nucleotide is delivered in 
the infected cells. We previously observed that the chemical 
stability of α-carboxylated phosphoramidates of nucleosides is 
base dependent.8 Some initial stability studies have been 
performed on the dA and dT analogues of compounds 18, 19 and 
20. All compounds are stable in neutral and basic (pH12)
medium. Degradation of the α-COOH compounds occurs in 
acidic circumstances, liberating dA or dT and the phosphorylated 
lipid within a few days at pH=6 and within minutes at pH=4. 
These results suggest that chemical degradation might not be the 
reason for delivering d4A inside cells, but this is not conclusive. 
The study in acidic circumstances has been performed in DMSO 
(as all compounds from gels in aqueous acetic medium) which 
questions the (biological) relevance of this experiment. It could 
therefore be possible that 20 is more easily enzymatically 
degraded in cells than 18, 19 or 21.  
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Table 1. Antiviral activity test of compounds against HIV-1 and HIV-2 
MT-4 cells a CEM/0 b CEM/TK- c 
Analogue 
IC50 (µM) 
HIV-1 
IC50 (μM) 
HIV-2 
CC50 (μM) IC50 (μM) 
HIV-2 
CC50 (µM) IC50 (μM)
HIV-2 
18 0.4±0.1 0.4±0.1 64.7±8.7 >39.6 92.6±9.5 >39.6
19 10.9±1.0 16.2±0.2 >198.2 >198.2 >198.2 >39.6
20 0.19±0.02 0.11±0.01 97.8±5.5 25.3 ± 12.7 81.3±8.7 >39.1 
21 9.7±2.5 5.7±0.1 94.1±8.8 7.5 ± 2.5 91.1±8.3 >40.5 
d4T 0.26±0.03 0.4±0.1 327.4±32.2 8.8 ± 6.4 >267.6 ≥ 119.7 
d4A >277.5 >277.5 277.5±19.2 ≥36.6 360.3±63.7 ≥81.9 
ddC 1.0±0.6 1.9±0.3 324.8±29.4 0.5±0.3 178.8±33.0 1.9±0.8 
AZT 0.007±0.002 0.007±0.002 >93.5 0.04±0.01 >467.7 >14.9
a HIV-1 (IIIB), HIV-2 (ROD); b CEM/0 cells (ROD); c CEM thymidine kinase deficient cells (ROD) 
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